Source: Υπουργείο Υγείας (CY) Revision Year: 2016 Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, P. O. Box 51706, 3056 Limassol, Cyprus
Clavomid 250 mg/125 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, oval, film-coated tablets. |
Each film-coated tablet contains amoxicillin trihydrate equivalent to 250 mg amoxicillin and diluted potassium clavulanate equivalent to 125 mg clavulanic acid.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Amoxicillin |
Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bactericidal peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death. |
|
| Clavulanic acid |
Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. |
| List of Excipients |
|---|
|
Core: Microcrystalline cellulose Coating: Hypromellose |
Aluminium/Aluminium blisters. Pack-size of 20 film-coated tablets.
Remedica Ltd, Aharnon Str., Limassol Industrial Estate, P. O. Box 51706, 3056 Limassol, Cyprus
19666
Date of first authorization: 16 May 2005
Date of latest renewal: 29 July 2013
| Drug | Countries | |
|---|---|---|
| CLAVOMID | Albania, Cyprus, Hong Kong |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
